File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study

TitleEffect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study
Authors
KeywordsAntibody
Booster
COVID-19
Hybrid immunity
T cell
Vaccination
Issue Date1-Jul-2023
PublisherElsevier
Citation
EBioMedicine, 2023, v. 88 How to Cite?
Abstract

Background Vaccination reduces COVID-19-related hospitalization among older adults. However, how SARS-CoV-2 infection and vaccine regimens affect vaccine-elicited immunity remain unclear.Methods This is a cross-sectional study recruiting adults aged >= 70 years with comorbidities in Hong Kong. Demographic and clinical information were collected using a questionnaire. Neutralizing antibody (nAb) titers (against ancestral and Omicron strains) and SARS-CoV-2-specific T cell response were analyzed according to infection and vaccination status. Multivariable regression analysis was performed to assess the associations of BNT162b2 and booster doses with higher nAb titers, with adjustment for comorbidities.Findings In July 2022, 101 patients were recruited, of whom 25 (24%) had previous infection. Overall, the geometric mean titer (GMT) of BA.5 nAb was 2.8-fold lower than that against BA.2 (P < 0.0001). The ancestral strain and BA.2 titers were higher for the 3-4-dose-BNT162 group than the 2-dose-BNT162b2 group. Non-infected individuals in the 3-4-dose-CoronaVac group had a more robust T cell response than the 2-dose-CoronaVac group (P = 0.0181), but there was no significant difference between the 2-dose-BNT162b2 and 3-4-dose-BNT162b groups. Patients who had heterologous CoronaVac-BNT162b2 prime-boost regimen had 3.22-fold higher BA.5 nAb titers than those who were primed/boosted with CoronaVac (P = 0.0207). Patients with hybrid immunity had higher Omicron nAb titers than those with vaccine-only immunity. Multivariable analysis showed that BNT162b2 and booster doses were independently associated with higher ancestral strain nAb titers.Interpretation Our data support the use of booster doses for older adults with or without prior infection. Non-infected individuals primed with CoronaVac will benefit from heterologous mRNA vaccine booster.


Persistent Identifierhttp://hdl.handle.net/10722/337174
ISSN
2023 Impact Factor: 9.7
2023 SCImago Journal Rankings: 3.193
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorFong, CH-
dc.contributor.authorZhang, X-
dc.contributor.authorChen, LL-
dc.contributor.authorPoon, RW-
dc.contributor.authorChan, BP-
dc.contributor.authorZhao, Y-
dc.contributor.authorWong, CK-
dc.contributor.authorChan, KH-
dc.contributor.authorYuen, KY-
dc.contributor.authorHung, IF-
dc.contributor.authorYuen, JKY-
dc.contributor.authorTo, KK-
dc.date.accessioned2024-03-11T10:18:40Z-
dc.date.available2024-03-11T10:18:40Z-
dc.date.issued2023-07-01-
dc.identifier.citationEBioMedicine, 2023, v. 88-
dc.identifier.issn2352-3964-
dc.identifier.urihttp://hdl.handle.net/10722/337174-
dc.description.abstract<p>Background Vaccination reduces COVID-19-related hospitalization among older adults. However, how SARS-CoV-2 infection and vaccine regimens affect vaccine-elicited immunity remain unclear.Methods This is a cross-sectional study recruiting adults aged >= 70 years with comorbidities in Hong Kong. Demographic and clinical information were collected using a questionnaire. Neutralizing antibody (nAb) titers (against ancestral and Omicron strains) and SARS-CoV-2-specific T cell response were analyzed according to infection and vaccination status. Multivariable regression analysis was performed to assess the associations of BNT162b2 and booster doses with higher nAb titers, with adjustment for comorbidities.Findings In July 2022, 101 patients were recruited, of whom 25 (24%) had previous infection. Overall, the geometric mean titer (GMT) of BA.5 nAb was 2.8-fold lower than that against BA.2 (P < 0.0001). The ancestral strain and BA.2 titers were higher for the 3-4-dose-BNT162 group than the 2-dose-BNT162b2 group. Non-infected individuals in the 3-4-dose-CoronaVac group had a more robust T cell response than the 2-dose-CoronaVac group (P = 0.0181), but there was no significant difference between the 2-dose-BNT162b2 and 3-4-dose-BNT162b groups. Patients who had heterologous CoronaVac-BNT162b2 prime-boost regimen had 3.22-fold higher BA.5 nAb titers than those who were primed/boosted with CoronaVac (P = 0.0207). Patients with hybrid immunity had higher Omicron nAb titers than those with vaccine-only immunity. Multivariable analysis showed that BNT162b2 and booster doses were independently associated with higher ancestral strain nAb titers.Interpretation Our data support the use of booster doses for older adults with or without prior infection. Non-infected individuals primed with CoronaVac will benefit from heterologous mRNA vaccine booster.<br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofEBioMedicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAntibody-
dc.subjectBooster-
dc.subjectCOVID-19-
dc.subjectHybrid immunity-
dc.subjectT cell-
dc.subjectVaccination-
dc.titleEffect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study-
dc.typeArticle-
dc.identifier.doi10.1016/j.ebiom.2023.104446-
dc.identifier.scopuseid_2-s2.0-85146642679-
dc.identifier.volume88-
dc.identifier.eissn2352-3964-
dc.identifier.isiWOS:000932040400001-
dc.identifier.issnl2352-3964-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats